MGX Metagenomi Therapeutics, Inc.
Nasdaq · SEC CIK 1785279 · EDGAR
- Bought, last 12 months
- $23.4K 1 purchases by 1 insiders
- Sold, last 12 months
- $33.1K 13 sales by 4 insiders
- Filings on record
- 58 since 2024-02-14, latest 2026-09-11 19:51
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Reid Laurence | Dir | $23.4K | — |
| Irish Jian | See Remarks, Dir | — | $12.7K |
| Wapnick Pamela | CFO | — | $11.3K |
| Thomas Brian C. | Dir | — | $6,779 |
| Wein Matthew | See Remarks | — | $2,263 |
Transactions 52
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-09-11 19:51 | 2026-09-09 | MGX | Reid Laurence | Dir | P - Purchase | $1.17 | +20.0K | 20.0K | New | +$23.4K |
| 2026-09-10 15:47 | 2026-09-08 | MGX | Wein Matthew | See Remarks | S - Sale | $1.16 | -358 | 126.1K | -0.3% | -$414.71 | |
| 2026-09-10 15:40 | 2026-09-08 | MGX | Irish Jian | See Remarks, Dir | S - Sale | $1.16 | -2,140 | 375.4K | -0.6% | -$2,479 | |
| 2026-09-10 15:34 | 2026-09-08 | MGX | Wapnick Pamela | CFO | S - Sale | $1.16 | -1,911 | 206.6K | -0.9% | -$2,214 | |
| 2026-06-10 11:23 | 2026-06-05 | MGX | Wapnick Pamela | CFO | S - Sale | $1.30 | -2,884 | 208.5K | -1% | -$3,746 | |
| 2026-06-10 11:21 | 2026-06-05 | MGX | Irish Jian | See Remarks, Dir | S - Sale | $1.30 | -3,737 | 377.5K | -1.0% | -$4,854 | |
| 2026-06-10 11:19 | 2026-06-05 | MGX | Wein Matthew | See Remarks | S - Sale | $1.30 | -558 | 126.5K | -0.4% | -$724.84 | |
| D | 2026-04-03 14:11 | 2026-04-01 | MGX | Irish Jian | See Remarks, Dir | A - Grant | $0.00 | +46.0K | 379.8K | +14% | $0 |
| D | 2026-04-03 14:00 | 2026-04-01 | MGX | Wein Matthew | See Remarks | A - Grant | $0.00 | +11.0K | 125.5K | +10% | $0 |
| D | 2026-04-03 13:40 | 2026-04-01 | MGX | Wapnick Pamela | CFO | A - Grant | $0.00 | +24.0K | 211.4K | +13% | $0 |
| 2026-03-09 | 2025-12-05 | MGX | Irish Jian | CEO, Dir | G - Gift | $0.00 | -228.5K | 335.4K | -41% | $0 | |
| 2026-03-09 | 2026-03-05 | MGX | Irish Jian | CEO, Dir | S - Sale | $1.60 | -1,607 | 333.8K | -0.5% | -$2,571 | |
| 2026-03-09 | 2026-03-05 | MGX | Wapnick Pamela | CFO | S - Sale | $1.60 | -1,581 | 187.4K | -0.8% | -$2,530 | |
| 2026-03-09 | 2026-03-05 | MGX | Wein Matthew | See Remarks | S - Sale | $1.60 | -482 | 114.5K | -0.4% | -$771.20 | |
| 2025-12-08 | 2025-12-05 | MGX | Wein Matthew | See Remarks | S - Sale | $1.77 | -199 | 115.0K | -0.2% | -$352.23 | |
| 2025-12-08 | 2025-12-05 | MGX | Irish Jian | CEO, Dir | S - Sale | $1.77 | -1,602 | 563.8K | -0.3% | -$2,836 | |
| 2025-12-08 | 2025-12-05 | MGX | Wapnick Pamela | CFO | S - Sale | $1.77 | -1,576 | 189.0K | -0.8% | -$2,790 | |
| 2025-12-08 | 2025-12-05 | MGX | Thomas Brian C. | Dir | S - Sale | $1.77 | -3,830 | 2.51M | -0.2% | -$6,779 | |
| 2025-12-01 | 2025-09-05 | MGX | Wein Matthew | See Remarks | S - Sale | $1.81 | -199 | 19.2K | -1% | -$360.19 | |
| 2025-12-01 | 2025-12-01 | MGX | Wein Matthew | See Remarks | A - Grant | $1.60 | +96.0K | 115.2K | +499% | +$153.6K | |
| 2025-12-01 | 2025-09-05 | MGX | Wapnick Pamela | CFO | S - Sale | $1.81 | -1,576 | 70.5K | -2% | -$2,853 | |
| 2025-12-01 | 2025-12-01 | MGX | Wapnick Pamela | CFO | A - Grant | $1.60 | +120.0K | 190.5K | +170% | +$192.0K | |
| DM | 2025-12-01 | 2025-12-01 | MGX | Irish Jian | CEO, Dir | A - Grant | $1.60 | +248.5K | 565.4K | +78% | +$397.6K |
| D | 2025-12-01 | 2025-09-05 | MGX | Irish Jian | CEO, Dir | S - Sale | $1.81 | -1,602 | 316.9K | -0.5% | -$2,900 |
| 2025-12-01 | 2025-09-05 | MGX | Thomas Brian C. | Dir | S - Sale | $1.81 | -2,701 | 2.51M | -0.1% | -$4,889 | |
| 2025-06-09 | 2025-06-06 | MGX | Noonberg Sarah B. | Chief Medical Off | S - Sale | $1.75 | -5,239 | 109.1K | -5% | -$9,168 | |
| 2025-06-09 | 2025-06-06 | MGX | Wein Matthew | See Remarks | S - Sale | $1.75 | -199 | 16.7K | -1% | -$348.25 | |
| 2025-06-09 | 2025-06-06 | MGX | Irish Jian | See Remarks, Dir | S - Sale | $1.75 | -6,390 | 315.5K | -2% | -$11.2K | |
| 2025-06-09 | 2025-06-06 | MGX | Wapnick Pamela | CFO | S - Sale | $1.75 | -1,576 | 72.1K | -2% | -$2,758 | |
| 2025-06-09 | 2025-06-06 | MGX | Thomas Brian C. | CEO, Dir | S - Sale | $1.75 | -10.8K | 2.52M | -0.4% | -$18.9K | |
| D | 2025-04-03 | 2025-04-01 | MGX | Irish Jian | See Remarks, Dir | A - Grant | $0.00 | +23.0K | 321.9K | +8% | $0 |
| DM | 2025-04-03 | 2025-04-01 | MGX | Wein Matthew | See Remarks | A - Grant | $0.00 | +7,425 | 13.1K | +130% | $0 |
| D | 2025-04-03 | 2025-04-01 | MGX | Thomas Brian C. | CEO, Dir | A - Grant | $0.00 | +32.0K | 2.53M | +1% | $0 |
| D | 2025-04-03 | 2025-04-01 | MGX | Noonberg Sarah B. | Chief Medical Off | A - Grant | $0.00 | +14.0K | 114.4K | +14% | $0 |
| D | 2025-04-03 | 2025-04-01 | MGX | Wapnick Pamela | CFO | A - Grant | $0.00 | +14.0K | 73.7K | +23% | $0 |
| 2025-03-07 | 2025-03-05 | MGX | Wein Matthew | See Remarks | S - Sale | $1.87 | -930 | 9,467 | -9% | -$1,739 | |
| 2025-03-07 | 2025-03-05 | MGX | Wapnick Pamela | CFO | S - Sale | $1.87 | -1,808 | 59.7K | -3% | -$3,381 | |
| 2024-12-06 | 2024-12-05 | MGX | Wapnick Pamela | CFO | S - Sale | $1.86 | -1,559 | 61.5K | -2% | -$2,900 | |
| 2024-09-06 | 2024-09-05 | MGX | Wapnick Pamela | CFO | S - Sale | $2.88 | -6,265 | 63.1K | -9% | -$18.0K | |
| D | 2024-04-03 | 2024-04-01 | MGX | Wapnick Pamela | CFO | A - Grant | $0.00 | +69.3K | 69.3K | New | $0 |
| D | 2024-04-03 | 2024-04-01 | MGX | Noonberg Sarah B. | Chief Medical Off | A - Grant | $0.00 | +57.8K | 100.4K | +136% | $0 |
| D | 2024-04-03 | 2024-04-01 | MGX | Irish Jian | See Remarks, Dir | A - Grant | $0.00 | +70.5K | 298.9K | +31% | $0 |
| D | 2024-04-03 | 2024-04-01 | MGX | Delaney Simren | See Remarks | A - Grant | $0.00 | +6,931 | 93.9K | +8% | $0 |
| D | 2024-04-03 | 2024-04-01 | MGX | Borges Luis | CSO | A - Grant | $0.00 | +69.3K | 69.3K | New | $0 |
| D | 2024-04-03 | 2024-04-01 | MGX | Thomas Brian C. | CEO, Dir | A - Grant | $0.00 | +119.0K | 2.50M | +5% | $0 |
| D | 2024-04-03 | 2024-04-01 | MGX | Harnest Simon | See Remarks | A - Grant | $0.00 | +11.6K | 122.7K | +10% | $0 |
| D | 2024-04-03 | 2024-04-01 | MGX | Wein Matthew | See Remarks | A - Grant | $0.00 | +10.4K | 10.4K | New | $0 |
| DM | 2024-02-15 | 2024-02-13 | MGX | Bayer World Investments B.V. | 10% | C - Cnv Deriv | — | +4.05M | 4.05M | New | — |
| DM | 2024-02-15 | 2024-02-09+ | MGX | Novo Holdings A/S | 10% | P - Purchase | $14.47 | +900.0K | 100.0K | New | +$13.03M |
| D | 2024-02-15 | 2024-02-13 | MGX | Novo Holdings A/S | 10% | C - Cnv Deriv | — | +839.2K | 939.2K | +839% | — |
| D | 2024-02-14 | 2024-02-13 | MGX | Bernales Sebastian | Dir | C - Cnv Deriv | — | +513.0K | 769.8K | +200% | — |
| DI | 2024-02-14 | 2024-02-13 | MGX | Bernales Sebastian | Dir | C - Cnv Deriv | — | +1.90M | 1.90M | New | — |
Purchase Sale Sale after option exercise All abbreviations